Increasing accessibility and government support to contribute towards the malaria vaccines market growth

Nearly half of the global population is at risk of malaria as per stats released by the World Health Organization (WHO). This in turn has led to increased inclination of various healthcare agencies towards addressing this major malady. Global non-profit organizations such as the Melinda Gates Foundation and PATH are working towards developing preventive measures and saving lives of many in the malaria affected regions. Africa accounts for the largest number of malaria cases and hence, this region is the primary target of launching the first malaria vaccine developed by GlaxoSmithKline plc. Mosquirix received EU approval in 2015 and is presently being examined in Africa as a pilot study.

People in Africa use insecticide-treated mosquito nets and indoor-insecticide spraying for prevention against malarial vectors. Use of insecticide-treated mosquito nets in Africa increased by 80% during 2010-2015 (WHO). Moreover, a number of mosquito repellent products (patches, creams, coils, mats, liquids, etc.) are marketed globally. Besides, non-profit organizations provide cheap and often free treatment facilities to the malarial affected population in Africa. Also, GSK has pledged to sell the vaccines at a much lower cost forgoing its huge profit margins to support the global malaria eradication programs. Furthermore, with more malarial vaccines under research pipeline, the malaria vaccines market is poised for significant growth in near future.

Request For Sample Copy@
https://www.coherentmarketinsights.com/insight/request-sample/37

The global malaria vaccines market is expected to be valued at US$ 8.5 million in 2018 and is expected to witness a CAGR of 102.8% during the forecast period (2018 – 2024).

Tremendous potential in the malaria vaccines market

Potential for malaria vaccines is estimated to be huge as a large share of population, 90%-95%, at risk of infection in Africa and South East-Asia. Advent of vaccines for adult population, would be a major breakthrough for the malaria vaccines market. Below are certain alarming statistics that embarks the need for a malaria vaccine:

Artemisinin resistance has been detected in five countries – Laos, Cambodia, Myanmar, Vietnam and Thailand
Resistance to P. falciparum parasite against the most available anti-malarial medicines is being reported
According to the National Vector Borne Disease Control Programme, nearly 95% of the population in India reside in malaria endemic areas
There were an estimated 214 million malaria cases globally in 2015 (WHO)
Africa is the most affected region with 90% of malarial deaths in 2015 reported in Africa (WHO)
Pregnant women, children below 5 years of age, and tourists from countries with low incidence rate of malaria are identified as the most susceptible target population for malaria
The global malaria vaccines market is expected to experience a huge trajectory growth with the launch of first malarial vaccine in near future.

Increasing accessibility and government support to contribute towards the malaria vaccines market growth

The WHO has established a Global Technical Strategy for Malaria 2016-2030 (GTS) in 2015 with certain defined goals, one of them aimed at eliminating malaria in at least 10 countries. Similarly, the Indian government has established Drug Distribution Centers (DDCs) and Fever Treatment Depots (FTDs) in the rural areas for providing easy access to anti-malarial drugs. Regular monitoring and surveillance by various government programs has helped to reduce malarial cases in India from 2.03 million in 2010 to 1.1 million in 2015. Support from such national and global initiatives will drive malaria vaccines market growth during the forecast period.

Many such non-profit organizations and pharmaceutical companies are conducting research on malaria vaccines. Approximately 31 trials are under progress for malaria vaccine development with a few being blood stage projects. Availability of funds and government support programs will encourage commercialization of product with successful trial results, thus boosting the malaria vaccines market growth trajectory.

The P. falciparum vaccines market is projected to be the growth driver with major vaccine candidates targeting this parasite. Revenues through community centers is projected to be high as demand for preventive treatment methods is high from this end-user segment.

Get More Details On this Report:
https://www.coherentmarketinsights.com/market-insight/malaria-vaccines-market-37

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.